Galderma Laboratories, L.P. announced today that the U.S. Food and Drug Administration (FDA) approved antibiotic-free Epiduo Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5%, for the once-daily, topical treatment of acne vulgaris. Acne is the most common skin condition in the United States, affecting more than 40 to 50 million people. Epiduo Forte Gel is the first combination of these strengths of the retinoid, adapalene, and benzoyl peroxide, developed for the moderate to severe acne population.

"As the industry leader in dermatology, Galderma recognizes the need for innovative acne medications across a spectrum of acne severities,” said Todd Zavodnick, President and General Manager of Galderma Laboratories, L.P. “The FDA approval of Epiduo Forte Gel has helped us expand on our robust acne franchise to deliver a safe, effective and antibiotic-free treatment to patients in need, and underscores Galderma’s continued commitment to skin health and antibiotic stewardship.”

For more details, go to: http://www.galdermausa.com/downloads/EPI-00017_Forte%20Approval%20Press%20Release_%207%2016%2015_Final.pdf